Literature DB >> 12637979

Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers.

T Kästenbauer1, B Hörnlein, G Sokol, K Irsigler.   

Abstract

AIMS/HYPOTHESIS: To re-evaluate the use of Granulocyte-Colony Stimulating Factor (G-CSF) in the treatment of infected diabetic foot ulcers.
METHODS: Thirty-seven diabetic subjects were randomised to Granulocyte-Colony Stimulating Factor (G-CSF) (n=20) or placebo (n=17). The primary endpoint was resolution of cellulitis, which was evaluated clinically and with an infection summary score. Patients were hospitalised for 10 days and received subcutaneously either 5 microg/kg G-CSF or placebo daily. Ulcers were treated with a standard wound protocol and the patients were instructed to stay in bed. All subjects received antibiotics (clindamycin and ciprofloxacin) intravenously until the inflammation had subsided.
RESULTS: Patients who received G-CSF did not have an earlier resolution of clinically defined cellulitis (p=0.57). The infection summary score declined, but comparably, in both groups (G-CSF: 29.5+/-18.4 to 6.7+/-6.3 p<0.001, placebo: 24.2+/-16.9 to 8.9+/-7.2 p<0.001). The ulcer volume, which was not greater among placebo patients, was reduced by 59% in G-CSF and by 35% in placebo patients. CONCLUSION/
INTERPRETATION: We conclude that antibiotic and non weight-bearing therapy (bed rest) accelerated the resolution of cellulitis in infected foot ulcers. Additional treatment with G-CSF had no further beneficial effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12637979     DOI: 10.1007/s00125-002-0998-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  7 in total

Review 1.  Diagnostics and treatment of the diabetic foot.

Authors:  Jan Apelqvist
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

2.  New insights in diabetic foot infection.

Authors:  Jean-Louis Richard; Albert Sotto; Jean-Philippe Lavigne
Journal:  World J Diabetes       Date:  2011-02-15

3.  Advancements in the Delivery of Growth Factors and Cytokines for the Treatment of Cutaneous Wound Indications.

Authors:  Caitlin Berry-Kilgour; Jaydee Cabral; Lyn Wise
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-11-25       Impact factor: 4.730

4.  From ulcer to infection: an update on clinical practice and adjunctive treatments of diabetic foot ulcers.

Authors:  C Abad; N Safdar
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

Review 5.  Optimising antimicrobial therapy in diabetic foot infections.

Authors:  Nalini Rao; Benjamin A Lipsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  The Role of Recombinant Proteins and Growth Factors in the Management of Diabetic Foot Ulcers: A Systematic Review of Randomized Controlled Trials.

Authors:  Elahe Mahdipour; Amirhossein Sahebkar
Journal:  J Diabetes Res       Date:  2020-07-11       Impact factor: 4.011

7.  Current concepts for the evaluation and management of diabetic foot ulcers.

Authors:  Andreas F Mavrogenis; Panayiotis D Megaloikonomos; Thekla Antoniadou; Vasilios G Igoumenou; Georgios N Panagopoulos; Leonidas Dimopoulos; Konstantinos G Moulakakis; George S Sfyroeras; Andreas Lazaris
Journal:  EFORT Open Rev       Date:  2018-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.